meglitinides
Small moleculeexperimental
Clinical trial activity
7 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
5
Phase 4
2
Earliest trial started Feb 1, 2011 (NCT01301833)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
KCNJ11 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4-(2-(5-chloro-2-methoxybenzamido)ethyl)benzoic acid
- hb 699
- meglitinide
- meglitinide
- meglitinide
- meglitinides
- meglitinides
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04809220 | Phase 3 | Apr 13, 2021 | Eli Lilly |
| NCT02954692 | Phase 4 | Nov 30, 2016 | Sanofi |
| NCT02730377 | Phase 4 | Mar 28, 2016 | Novo Nordisk |
| NCT01940965 | Phase 3 | Sep 1, 2013 | Sanofi |
| NCT01777282 | Phase 3 | Feb 23, 2013 | GlaxoSmithKline |
| NCT01468181 | Phase 3 | Nov 1, 2011 | Eli Lilly |
| NCT01301833 | Phase 3 | Feb 1, 2011 | Mitsubishi Tanabe, University of Tokyo |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 2 | 2 | 1 | 2011 |
| Sanofi | For profit | 2 | 2 | 2 | 2013 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2013 |
| Mitsubishi Tanabe | For profit | 1 | 1 | 1 | 2011 |
| Novo Nordisk | For profit | 1 | 1 | 1 | 2016 |
| University of Tokyo | Academic/Hospital | 1 | 0 | 1 | 2011 |
6 organizations
Page 1 / 1